Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics.
Identifying Potential Markers for Monitoring Progression to Ovarian Cancer Using Plasma Label-free Proteomics.
复制标题
DOI：
10.7150/jca.50733
复制
发表时间：
2021
影响因子：
3.9
通讯作者：
Li K
中科院分区：
文献类型：
--
作者：
Wang W;Xie H;Xia B;Zhang L;Hou Y;Li K
背景：癌抗原125（CA125）被认为对卵巢癌具有较高的敏感性，但特异性较差。目前迫切需要新的生物标志物来早期检测和监测卵巢癌患者的进展。研究方法：采用异序标记相对绝对定量（iTRAQ）法对80例卵巢癌患者（其中早期卵巢癌16例，晚期卵巢癌17例，良性卵巢肿瘤23例，子宫肌瘤24例）的血浆蛋白质组学进行分析，筛选卵巢癌患者的差异蛋白质。通过ELISA分析，检查了由具有相同匹配原则的独立样本队列收集的9个早期、11个晚期、17个BOT和16个UF的验证集，以确认差异表达蛋白的表达水平。结果：CRP和ARHGEF 11是卵巢癌潜在的诊断标志物.曲线下面积（AUC）分析结果表明，诊断蛋白和CA 125的组合与CA 125单独相比获得了更高的诊断准确性（AUC值：0.98 vs 0.80），特别是提高了特异性（0.97 vs 0.77）。此外，血浆CRP水平升高与卵巢癌风险增加相关。结论：目前研究发现，血浆蛋白CRP是监测卵巢癌进展的一个指标。联合检测血清蛋白标志物和CA125可用于卵巢癌的早期诊断。
Background: Cancer antigen 125 (CA125) is considered to have high sensitivity but poor specificity for ovarian cancer. New biomarkers utilized to early detect and monitor the progression of ovarian cancer patients are critically needed. Methods: A total of 80 patients including 16 early stage, and matched with 17 late stage, 23 benign ovarian tumor (BOT) and 24 uterine fibroid (UF) patients were utilized to perform plasma proteomics analysis using isobaric tag for relative and absolute quantitation (iTRAQ) method to identify differential diagnostic proteins of ovarian cancer patients. A validation set of 9 early stage, 11 late stage, 17 BOT and 16 UF collected by an independent cohort of samples with the same matching principles was examined to confirm the expressed levels of differential expression proteins by ELISA analysis. Results: CRP and ARHGEF 11 were identified as potential diagnostic biomarkers of ovarian cancer. Results of area under the curve (AUC) analysis suggested that combination of diagnostic proteins and CA125 achieved a much higher diagnostic accuracy compared with CA125 alone (AUC values: 0.98 versus 0.80), especially improved the specificity (0.97 versus 0.77). In addition, elevated plasma CRP levels were associated with increased risk of ovarian cancer. Conclusions: Current study found that plasma protein CRP was an indicator for monitoring the progression of ovarian cancer. Combination of plasma protein biomarkers with CA125 could be utilized to early diagnose of ovarian cancer patients.
登录
查看更多内容
影响因子：
4.7
作者：
Lee, Seounghee;Choe, Jae-Won;Sung, Joohon
通讯作者：
Sung, Joohon
羊草叶蛋白质组动力学和短期盐胁迫的生理反应
影响因子：
3.7
作者：
Li J;Cui G;Hu G;Wang M;Zhang P;Qin L;Shang C;Zhang H;Zhu X;Qu M
通讯作者：
Qu M
影响因子：
5.6
作者：
Mizuki Y;Takaki M;Sakamoto S;Okamoto S;Kishimoto M;Okahisa Y;Itoh M;Yamada N
通讯作者：
Yamada N
影响因子：
4.7
作者：
Lavie, Ofer;Chetrit, Angela;Zoltan, Ahuva
通讯作者：
Zoltan, Ahuva
影响因子：
2.5
作者：
Pappa, Kalliopi I.;Lygirou, Vasiliki;Anagnou, Nicholas P.
通讯作者：
Anagnou, Nicholas P.